Abstract
Factor V:Q506 ( factor V Leiden) is associated with venous thrombosis and has been reported to be a risk factor for retinal Vein occlusion (RVO), Anticardiolipin antibodies (ACA), also associated with RVO, are a marker for the prothrombotic condition antiphospholipid syndrome, in which antiendothelial antibodies (AECA) are also frequently present. This study reviewed 45 younger patients less than or equal to 55 years old (21 with branch, 22 with central and 2 with hemispheric RVO) to examine: (1) the role of factor V:Q506 in the pathogenesis of RVO, and (2) the prevalence and titre of ACA and AECA in this group. No patient had the factor V:Q506 mutation indicating no increase in frequency above background. Our data suggest that primary screening for factor V:Q506 is not indicated for young patients with RVO who do not have historical evidence suggesting familial thrombophilia. Twenty-nine patients had low-titre ACA (> 10 GPL units); in 6 of these, the titre was > 20 GPL units (population reference range = 0-10 GPL units). No patient had antiendothelial cell reactivity. The low-titre ACA may therefore represent a non specific response to vascular injury. Copright (C) 2001 S.Karger AG, Basel.
Original language | English |
---|---|
Pages (from-to) | 217-221 |
Number of pages | 4 |
Journal | Ophthalmologica |
Volume | 215 |
Issue number | 3 |
DOIs | |
Publication status | Published - 2001 |
Keywords
- retinal vein occlusion
- factor V : Q506
- factor V Leiden
- antiphospholipid syndrome
- antiendothelial cell antibody
- protein C
- activated protein C resistance
- ACTIVATED PROTEIN-C
- PRIMARY ANTIPHOSPHOLIPID SYNDROME
- FACTOR-V-LEIDEN
- VENOUS THROMBOSIS
- VASOOCCLUSIVE RETINOPATHY
- ARTERIAL-OCCLUSION
- VASCULAR-DISEASE
- RISK FACTOR
- RESISTANCE
- GENE